Clinical Trials

11 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Phase 1 Recruiting

81 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04394650 2024-07-26

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

78 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Other hematologic neoplasmPlasma cell

42 enrolled

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1 Unknown

29 enrolled

NCT00664898 2022-12-12

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

18 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

26 enrolled

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00532389 2020-12-19

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

62 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00532675 2020-12-19

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

46 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01456689 2020-12-17

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

79 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02955550 2020-07-22

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03999697 2019-06-27

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Phase 1 Unknown

10 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

38 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

48 enrolled 26 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00446342 2017-04-11

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

21 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT02369029 2016-03-09

BAY1238097, First in Man

DermatologicLymphoidPlasma cell

8 enrolled

Lymphoma, Melanoma, Neoplasms, Neoplasms, Plasma Cell

NCT00594126 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

20 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00718601 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

40 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01344876 2015-06-08

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

20 enrolled 6 charts

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

30 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00891137 2014-10-27

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

30 enrolled

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00070616 2014-10-24

Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

LymphoidOtherOther hematologic neoplasmPlasma cell

25 enrolled

Leukemia, Lymphoma, Mucositis, Neoplasms, Plasma Cell

NCT00725634 2014-01-27

P05538

41 enrolled

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

NCT00825487 2011-10-19

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

50 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Neoplasm Metastasis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00460460 2011-01-25

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

75 enrolled

Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours